Interestingly, blocking CXCR4 by AMD3100 increased T-cell infiltration in mouse models of breast cancer with high efficacy when combined with anti-PD-1 and anti-CTLA-4 treatments [224]. Here, CXCR4 is linked to breast carcinoma.